Literature DB >> 16621193

HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

Joseph F Bower1, Yuxing Li, Richard Wyatt, Ted M Ross.   

Abstract

Currently, no vaccine for human immunodeficiency virus (HIV-1) provides protection from virus infection. One reason for these disappointing results has been the difficulty of current vaccine candidates to elicit high-titer, broadly reactive immunity to a large number of viral proteins. Recently, our laboratory demonstrated that the coupling of C3d to a soluble trimerized HIV-1 envelope (Env(gp140(FT))) elicited higher titers of neutralizing antibodies than monomers of Env(gp120) coupled to C3d [Bower JF, Yang X, Sodroski J, Ross TM. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 2004;78(9):4710-9]. To determine if the induction of conformational antibodies correlated with neutralization, mice (BALB/c) were primed (2x) with DNA plasmids expressing monomeric Env(gp120) or trimeric Env(gp140) alone or fused to mC3d(3) at one of two doses (2.0microg or 0.2microg), followed by a boost of recombinant uncleaved, trimeric Env(gp140). Regardless of the priming dose of DNA, all mice had high-titer anti-Env IgG antibodies. Interestingly, Env(gp140) trimers did not elicit higher titers of antibodies that recognized conformational Env epitopes compared to monomers of Env(gp120). Therefore, additional parameters were examined for correlation with neutralization. For neutralization-resistant HIV-1 isolates, ADA and YU-2, neutralization correlated with high-titer, high avidity antibodies, with Env(gp140) eliciting slightly higher neutralization titers than Env(gp120). In contrast, none of the measured parameters correlated with neutralization for the more neutralization-sensitive isolates, MN or 89.6. Therefore, even though soluble, uncleaved Env(gp140) trimers may be marginally more effective at eliciting neutralizing antibodies than Env(gp120), neutralization does not appear to correlate with the elicitation of conformationally dependent antibodies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621193     DOI: 10.1016/j.vaccine.2006.03.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

2.  An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.

Authors:  Yajing Chen; Richard Wilson; Sijy O'Dell; Javier Guenaga; Yu Feng; Karen Tran; Chi-I Chiang; Heather E Arendt; Joanne DeStefano; John R Mascola; Richard T Wyatt; Yuxing Li
Journal:  J Immunol       Date:  2016-10-10       Impact factor: 5.422

3.  Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells.

Authors:  Subhabrata Biswas; Hong Chang; Phuong T N Sarkis; Erol Fikrig; Quan Zhu; Wayne A Marasco
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

4.  Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

Authors:  Yanmin Wan; Lan Wu; Lianxing Liu; Jianqing Xu; Ying Liu; Yong Liu; Yiming Shao
Journal:  Vaccine       Date:  2007-02-26       Impact factor: 3.641

5.  Emerging studies of human HIV-specific antibody repertoires.

Authors:  Mark D Hicar; Spyros A Kalams; Paul W Spearman; James E Crowe
Journal:  Vaccine       Date:  2010-05-26       Impact factor: 3.641

6.  Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Authors:  Joseph P Nkolola; Hanqin Peng; Ethan C Settembre; Michael Freeman; Lauren E Grandpre; Colleen Devoy; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Ritu Bradley; David C Montefiori; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

7.  Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.

Authors:  Sean X Du; Rebecca J Idiart; Ellaine B Mariano; Helen Chen; Peifeng Jiang; Li Xu; Kristin M Ostrow; Terri Wrin; Pham Phung; James M Binley; Christos J Petropoulos; John A Ballantyne; Robert G Whalen
Journal:  Virology       Date:  2009-10-08       Impact factor: 3.616

8.  Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.

Authors:  Hermancia S Eugene; Brooke R Pierce-Paul; Jodi K Cragio; Ted M Ross
Journal:  Virol J       Date:  2013-04-02       Impact factor: 4.099

9.  Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.

Authors:  Andreas Puschnik; Louis Lau; Elizabeth A Cromwell; Angel Balmaseda; Simona Zompi; Eva Harris
Journal:  PLoS Negl Trop Dis       Date:  2013-06-13

10.  Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Authors:  Tessa Dieltjens; Leo Heyndrickx; Betty Willems; Elin Gray; Lies Van Nieuwenhove; Katrijn Grupping; Guido Vanham; Wouter Janssens
Journal:  Retrovirology       Date:  2009-12-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.